Background
==========

Hepatocellular carcinoma (HCC) is one of the major human malignant tumors worldwide. Accumulation of genetic and epigenetic changes plays an important role in the process of hepatocarcinogenesis. Chromosomal aberration is among the most prevalent genetic alterations observed in HCC \[[@B1]\]. Recurrent chromosomal gains of 1q, 6p, 8q, 17q, and 20q, and losses of 1p, 4q, 5q, 6q, 8p, 9p, 10q, 13q, 16q, 17p, 19p, and 22q in HCC have been documented in previous studies \[[@B2]-[@B7]\]. Exploring cancer genome in great details always led to the identification of cancer-associated genes (also referred to as *target genes*) located within the amplified or deleted chromosomal regions. For example, deletion at 1p36 locus in HCC was reported to be one of the common mechanisms for inactivation of RUNX3, a putative tumor suppressor gene located within this region \[[@B8]\]. Elevated expression level of PTK2 and EIF3S3 genes in HCC was demonstrated to be significantly correlated with amplification of 8q23-q24, indicating a potential role for these genes in progression of HCC \[[@B9]\].

Recent innovations on molecular genetic techniques allowed investigators to perform genome-wide analysis of chromosomal aberrations at high resolution. Among these techniques, array-based comparative genomic hybridization (aCGH), high-density single nucleotide polymorphism (SNP) arrays and digital karyotyping have been proved to be the most effective tools in discovering abnormal chromosomal features \[[@B7],[@B10],[@B11]\]. Instead of generating analog signal intensity in the array-based methods, digital karyotyping is characterized by providing direct, unbiased, precise and quantitative measurement of chromosomal aberrations, with a theoretical resolution as high as 0.004 Mb \[[@B12]\].

In the current study, digital karyotyping was applied to detect chromosomal aberrations in HCC. We found that the amplification at 7q21.3 locus may contribute to the development or progression of HCC. Gains of 7q21 have been observed in tumors such as prostate cancer, colorectal cancer and HCC \[[@B13]-[@B15]\]. Tsuji *et al*. has identified PEG10 as a putative oncogene located within the amplified 7q21 locus in HCC \[[@B16]\]. Our study highlighted that more target genes including SGCE, DYNC1I1, SLC25A13, as well as PEG10, were harbored within the amplicons at 7q21.3 in HCC. Furthermore, up-regulation of SGCE, DYNC1I1 and PEG10 genes were also observed in HCC. These results indicated that amplification of 7q21.3 may be involved in carcinogenesis of HCC, and SGCE, DYNC1I1 and PEG10 were candidate oncogenes located within 7q21.3 locus.

Methods
=======

Tissue samples
--------------

Clinical tumorous and corresponding non-tumorous liver tissues were obtained from HBV-positive primary HCC patients who underwent curative surgery. Specimens were kept frozen in liquid nitrogen immediately to avoid any degradation of RNA and/or DNA. Blood of normal individuals was obtained from healthy people who underwent regular physical examination. All samples were collected with informed consent and the study was approved by the Institutional Human Subjects Protection Review Board.

Digital karyotyping
-------------------

Genomic DNA was isolated from one tumorous liver tissue using DNeasy kit (Qiagen) according to the manufacture\'s instruction. Then, 10 μg of genomic DNA was used to generate digital karyotyping library as described by Leary et al \[[@B17]\]. However, the concatemers of ditags were not cloned into pZero because 454 Genome Sequencer FLX System (Roche) was applied in large scale sequencing in this study. Instead, the concatemers with adhesive ends of CATG were ligated to a pair of modified adaptors A^+^and B^+^which provide priming regions for the following emulsion PCR and 454 pyrosequencing. The original Adaptor A and B provided by the GS FLX Standard DNA Library Preparation Kit (Roche) were blunt-ended and could not be ligated to concatemers directly. Thus, we designed a modified Adaptor A^+^and B^+^with an extruding end which was complementary to the adhesive end of concatemers. The sequences of Adaptor A^+^and B^+^were as followings: Adaptor A^+^forward strand: 5\'-CCA TCT CAT CCC TGC GTG TCC CAT CTG TTC CCT CCC TGT CTC AG[A CTG]{.ul}CAT G-3\'; Adaptor A^+^reverse strand: 5\'-[CAG T]{.ul}CT GAG ACA GGG AGG GAA CAG ATG GGA CAC GCA GGG ATG AG-3\'; Adaptor B^+^forward strand: 5\'-Biotin-CCT ATC CCC TGT GTG CCT TGC CTA TCC CCT GTT GCG TGT CTC AG[A CTG]{.ul}CAT G-3\'; Adaptor B^+^reverse strand: 5\'-[CAG T]{.ul}CT GAG ACA CGC AAC AGG GGA TAG GCA AGG CAC ACA GGG GA-3\'. The underlined basepairs were optional barcode sequences. The following procedures were carried out according to the original protocol \[[@B18]\], and sequencing run was performed on 454 GS FLX instrument. The 21 bp genomic tags were extracted using SAGE2000 software (Invitrogen). The experimentally observed tags were mapped to virtual tags on the genome and their relative frequency was counted to detect genomic amplifications and deletions using Digital Karyotyping Data Viewer software <http://cgap.nci.nih.gov/SAGE/DKViewHome>. The database of virtual genomic tags was established according to sequences of NCBI Human Genome Assembly Build 37 (released on Aug 2009).

Quantitative PCR
----------------

Genomic DNAs were extracted from tumorous liver tissues of 52 HCC patients and peripheral blood lymphocytes of 52 normal individuals using DNeasy kit (Qiagen). PCR reaction mixture of 25 μl was composed of 50 ng genomic DNA, 12.5 μl SYBR Premix Ex Taq (TaKaRa), 250 nM of each primer and appropriate volume of ddH~2~O. The thermal cycles were performed on ABI Prism 7300 apparatus (Applied Biosystems) with conditions of 95°C for 10 s, followed by 40 cycles of 95°C for 5 s and 60°C for 30 s. Each PCR reaction was performed in triplicate and threshold cycle numbers were averaged. The primers (Table [1](#T1){ref-type="table"}) were designed using Primer 3 software <http://frodo.wi.mit.edu/primer3/>. The repetitive element LINE-1, which is likely to has an equivalent copy number in cancer and normal genomes, was used as an endogenous control for normalization of DNA content.

###### 

Primers used for real-time quantitative PCR

  ----------------------------------------------------
  Genes      Primers                    Product Size
  ---------- -------------------------- --------------
  LINE-1     F: AAAGCCGCTCAACTACATGG\   149 bp
             R: TGCTTTGAATGCGTCCCAGAG   

  SGCE       F: CAGAGACCTTGCTTCCCTTG\   193 bp
             R: CGTCTTATCAGCCACTGCAA    

  DYNC1IC    F: ATACAGGACACCCAGGCAAG\   138 bp
             R: ACTTCTCGGACCATGTCAGG    

  SLC25A13   F: AGGCAGAGCTGGCAAAATAA\   105 bp
             R: TCATGCCTTTTTGATGTGGA    

  PEG10      F: CCAGTTGTCATCCACCACAG\   219 bp
             R: TGCAATTTTCCACAGACCAA    
  ----------------------------------------------------

Quantitative reverse transcription-PCR (RT-PCR)
-----------------------------------------------

Total RNAs were extracted from 32 pairs of tumorous and corresponding non-tumorous liver tissues using TRIzol reagent (Invitrogen), and then treated with RNase-free DNaseI (Promega) prior to reverse transcription. The reverse transcription reactions and following quantitative PCR reactions, as well as statistical analysis were done as previously described \[[@B19]\]. GAPDH was used as internal control for normalizing mRNA level. The sequences of primers used for quantitative RT-PCR were listed in Table [2](#T2){ref-type="table"}.

###### 

Primers used for real-time quantitative RT-PCR

  ------------------------------------------------------
  Genes      Primers                      Product Size
  ---------- ---------------------------- --------------
  GAPDH      F: ATGGGTGTGAACCATGAGAAG\    106 bp
             R: AGTTGTCATGGATGACCTTGG     

  SGCE       F: ATGCAAACACCAGACATCCA\     220 bp
             R: TCTGATGTGGCAAGTTCTGC      

  DYNC1IC    F: TGTGGTCCCCCGTGCATCCT\     127 bp
             R: AGGGCGGATGCCCCCTCAAT      

  SLC25A13   F: TGGCTGAGGCCCAGAGGCAG\     106 bp
             R: GCTCCAGCAACAGAACCCAGACC   

  PEG10      F: TCCTGTCTTCGCAGAGGAGT\     111 bp
             R: TTCACTTCTGTGGGGATGGA      
  ------------------------------------------------------

Statistical analysis
--------------------

Student\'s *t*test and Bonferroni correction were applied in the statistical analysis of quantitative PCR and RT-PCR data.

Results
=======

Digital karyotyping of HCC
--------------------------

We applied 454 pyrosequencing in the current study, and obtained a total of 821,252 genomic tags from the digital karyotyping library of HCC, among which 529,162 tags could be mapped to unique loci of human genome (i.e. filtered tags). By aligning these filtered tags across each chromosome using Digital Karyotyping Data Viewer software with a window size of 20, we identified multiple subchromosomal regions of amplification (fold change ≥3) and deletion (fold change ≤0.1) (Additional file [1](#S1){ref-type="supplementary-material"}). Among all these chromosomal aberrations, gains of chromosome 7 were of most interest. As many as fifty amplicons with sizes ranging from 287 bp to 212,814 bp were detected on the q arm of chromosome 7, some of which harbored known genes while some did not (Table [3](#T3){ref-type="table"}). The amplified subchromosomal region between 116,320,004 bp and 116,359,984 bp of 7q31 harbored MET gene, a well-known oncogene involved in hepatocarcinogenesis \[[@B20],[@B21]\]. The SGCE gene previously reported to be up-regulated in HCC by our group \[[@B19]\], was identified to reside within an amplicon at 94,187,248 bp\--94,227,832 bp of 7q21.3. According to the power calculation method developed by Salani *et al*, a 3-fold amplification covering 38 kb could be detected with a positive predictive value (PPV) ≥95% if 890,628 experimental tags were obtained \[[@B22]\]. Thus, with 821,252 tags available in this study, the PPV of detecting a 3-fold amplification of 40,584 bp which spans SGCE gene was supposed to be approximately 95%. We also observed that another two genes, DYNC1I1 and SLC25A13 located closely to SGCE, were contained within the amplicons at 7q21.3. Gene expression profile analysis of HCC has implied that SGCE and PEG10 harbored within 7q21.3 locus were putative tumor-associated genes \[[@B19]\]. Thus, our further investigation was focused on 7q21.3 locus, trying to find out more candidate protooncogenes within this amplified subchromosomal region.

###### 

Amplicons on chromosome 7 detected by digital karyotyping

  No. of amplicons   Start Position (bp)   End Position (bp)   Amplification Size (bp)   Known genes contained within amplicons
  ------------------ --------------------- ------------------- ------------------------- -----------------------------------------------
  1                  85669352              85675348            5996                      \--
  2                  90176250              90233199            56949                     PFTK1
  3                  92170683              92181579            10896                     \--
  4                  92402830              92489679            86849                     CDK6
  5                  92525776              92559603            33827                     \--
  6                  92621928              92628443            6515                      \--
  7                  94153659              94160414            6755                      CASD1
  8                  94187248              94227832            40584                     ***SGCE***
  9                  95575453              95593279            17826                     ***DYNC1I1***
  10                 95625240              95626171            931                       ***DYNC1I1***
  11                 95626365              95634906            8541                      ***DYNC1I1***
  12                 95857177              95888724            31547                     ***SLC25A13***
  13                 95984342              95992052            7710                      \--
  14                 96016428              96091391            74963                     \--
  15                 96091675              96098719            7044                      \--
  16                 96223512              96436326            212814                    SHFM1
  17                 96566511              96585224            18713                     \--
  18                 100008093             100031196           23103                     ZCWPW1, MEPCE
  19                 100188936             100202216           13280                     FBXO24, PCOLCE
  20                 100212010             100322730           110720                    MOSPD3, TFR2, ACTL6B, GNB2, GIGYF1, POP7, EPO
  21                 100514082             100516140           2058                      \--
  22                 100594842             100615369           20527                     MUC12
  23                 100619990             100633128           13138                     MUC12
  24                 100899076             100900255           1179                      \--
  25                 100920401             100933959           13558                     \--
  26                 101043124             101046675           3551                      EMID2
  27                 101047291             101056595           9304                      EMID2
  28                 101542859             101587823           44964                     CUX1
  29                 101708443             101725375           16932                     CUX1
  30                 116320004             116359562           39558                     MET
  31                 116359697             116359984           287                       MET
  32                 116516633             116651559           134926                    CAPZA2, ST7, ST7OT1, ST7OT4
  33                 116832388             116859422           27034                     ST7, ST7OT3
  34                 116986284             117113342           127058                    ASZ1
  35                 117258567             117275904           17337                     CFTR
  36                 117301541             117312368           10827                     CFTR
  37                 117348151             117357569           9418                      CTTNBP2
  38                 117371511             117376667           5156                      CTTNBP2
  39                 117487299             117511084           23785                     CTTNBP2
  40                 117575700             117576160           460                       \--
  41                 117604668             117718500           113832                    \--
  42                 117727390             117773948           46558                     \--
  43                 117862904             117882935           20031                     ANKRD7
  44                 117888893             117908976           20083                     \--
  45                 118228295             118274830           46535                     \--
  46                 118275399             118309895           34496                     \--
  47                 118442613             118473838           31225                     \--
  48                 118574464             118640670           66206                     \--
  49                 149702946             149746115           43169                     \--
  50                 153635222             153636533           1311                      DPP6

Genomic amplification of SGCE, PEG10, DYNC1I1 and SLC25A13 in HCC
-----------------------------------------------------------------

To validate genomic amplifications of SGCE, DYNC1I1 and SLC25A13 detected by digital karyotyping analysis, real-time quantitative PCR was performed in 52 HCC samples and 52 normal individuals. PEG10, a gene located very closely to SGCE in a head-to-head manner, was also selected for examination as a positive control, because both amplification and up-regulation of PEG10 have been observed in HCC \[[@B16],[@B23]\]. The schematic illustration of genes located within subchromosomal region of 7q21.3 (from 94,187,248 bp to 95,968,724 bp) was shown in Figure [1](#F1){ref-type="fig"}. Amplification of genomic DNA was defined as the DNA level of a HCC sample exceeded the mean plus 2 standard deviations of 52 normal individuals \[[@B24]\]. As shown in Figure [2](#F2){ref-type="fig"}, genomic amplification of SGCE, PEG10, DYNC1I1 and SLC25A13 was observed in 11 (21%), 11 (21%), 11 (21%) and 23 (44%) of the 52 HCC samples respectively. In the cases of SGCE, PEG10, and SLC25A13 genes, significant differences were observed between HCC samples and normal individuals, with *p*\< 0.05 after Bonferroni correction. However, the DYNC1I1 gene was likely to be a nominal one, with *p*value of 0.07 after Bonferroni correction (Additional File [2](#S2){ref-type="supplementary-material"}).

![**Schematic map of amplicons at 7q21.3 in HCC**. (A) Digital karyotyping analysis of chromosome 7 in HCC revealed amplicons at 7q21.3 (indicated by blue bars). (B) Zoom in of the 7q21.3 amplicons. (C) RefSeq genes located within the 7q21.3 amplicons.](1755-8794-4-60-1){#F1}

![**Real-time quantitative PCR validation of digital karyotyping data**. Totally 52 normal individuals and 52 HCC samples were examined for genomic DNA level of (A) SGCE, (B) PEG10, (C) DYNC1I1 and (D) SLC25A13 respectively by real-time quantitative PCR. The purple horizontal line represented an average of genomic DNA level of each group. HCC samples which gained genomic amplification of examined genes were shown by red squares.](1755-8794-4-60-2){#F2}

Up-regulated expression of SGCE, PEG10 and DYNC1I1 in HCC
---------------------------------------------------------

The transcript expression level of SGCE, PEG10, DYNC1I1 and SLC25A13 genes in tumorous and paired nontumorous tissues were examined in 32 HCC patients by real-time quantitative RT-PCR. As shown in Figure [3](#F3){ref-type="fig"} and Additional File [3](#S3){ref-type="supplementary-material"}, mRNA expression level of SGCE, PEG10 and DYNC1I1 genes were up-regulated in tumorous liver tissues compared with corresponding nontumorous counterparts. However, no significant difference was observed in expression level of SLC25A13 between tumorous and nontumorous liver tissues (data not shown). Taken together, these results suggested that SGCE, PEG10 and DYNC1I1 were putative oncogenes at the amplified 7q21.3 locus in HCC.

![**Up-regulated gene expression of SGCE, PEG10 and DYNC1I1 in HCC**. Real-time quantitative RT-PCR was performed in 32 pairs of HCC and corresponding nontumorous liver tissues. Significant up-regulation of mRNA expression level in HCC was observed in SGCE and PEG10 genes (*p*\< 0.05 after Bonferroni correction), and DYNC1I1 was considered as a nominal gene differently expressed in HCC with *p*value of 0.09 after Bonferroni correction. Blue bars represented expression level of HCC tumorous tissues, red bars represented nontumorous liver tissues, and horizontal bars represented SD values.](1755-8794-4-60-3){#F3}

Discussion
==========

In the present study, we applied 454 GS FLX, one of the next-generation sequencing systems, in large-scale sequencing of digital karyotyping library of HCC. To the best of our knowledge, no digital karyotyping data of HCC has been published in public. In most of the digital karyotyping libraries of human brain and colon available from public database <http://cgap.nci.nih.gov/SAGE/DKViewHome>, tags matched to human genome sequences accounted for 62\~69% of total genomic tags (Additional File [4](#S4){ref-type="supplementary-material"}). In our sequencing results, 64% (529,162) of the total 821,252 genomic tags were mapped tags, which was quite consistent with published data. Sequentially aligning these tags along each chromosome led to detection of subtle subchromosomal alterations occurred in HCC, among which the amplification of 7q21.3 drew our special attention.

The role of 7q21 amplification either in HCC cell lines or in primary HCC tumors have been implicated in previous studies \[[@B16],[@B23],[@B25]\]. However, within the subchromosome region7q21.3, only PEG10 has been identified as a potential target gene related to progressive development of HCC \[[@B16],[@B23]\]. Our study suggested that another two genes, SGCE and DYNC1I1, may also be HCC-related protooncogenes within the 7q21.3 locus. Genomic amplification of PEG10, SGCE, DYNC1I1 and SLC25A13 were detected by digital karyotyping analysis of HCC, and validated through real-time quantitative PCR. Among 52 HCC samples we examined, eleven (21%) of them showed genomic amplification of SGCE, PEG10 and DYNC1I1 respectively, and 23 (44%) of them exhibited genomic amplification of SLC25A13. Further examinations on mRNA expression level of these genes found that SGCE, PEG10 and DYNC1I1 were significantly up-regulated in HCC tumorous tissues compared with the paired nontumorous counterparts. Taken together, these findings indicated that in addition to PEG10, SGCE and DYNC1I1 were likely to be candidate targets for the 7q21.3 locus in HCC.

PEG10 has been identified as a putative target gene for the amplification at 7q21, as well as a progression related biomarker for HCC \[[@B16],[@B23]\]. SGCE, the epsilon member of sarcoglycan family, was demonstrated to be involved in myoclonus-dystonia syndrome (MDS) which is characterized by rapid myoclonic jerks and dystonia \[[@B26]\]. Recent studies shed light on a role SGCE may play in tumors, as it was up-regulated in a parallel way with PEG10 in both B-cell chronic lymphocytic leukemia and HCC, and showed low or null microsatellite instability in colorectal cancer \[[@B19],[@B27],[@B28]\]. However, since the function of SGCE and the mechanism of how it participate in tumor progression remains unknown up to now, its differential expression in HCC could only be regarded as a potential tumor-related marker without any concrete function.

DYNC1I1 gene encoded dynein intermediate chains 1, a component of cytoplasmic dynein complex, and participated in recognizing, binding and transporting vesicles, proteins, and RNAs *et al*\[[@B29],[@B30]\]. DYNC1I1 was also reported to be a reliable positive marker in testing bone marrow stromal cells prepared for tissue engineering and cell therapy \[[@B31]\]. Our study indicated DYNC1I1 was amplified and up-regulated in HCC, pointing to a possible association between this gene and hepatocarcinogenesis. Further studies on DYNC1I1 as well as SGCE are needed to explain the exact roles they may play in HCC and/or other tumors.

Conclusions
===========

In this study, we examined chromosomal aberrations of HCC on a genome-wide scale and found that subchromosomal region of 7q21.3 was amplified in HCC. Genomic amplification of PEG10, SGCE, DYNC1I1 and SLC25A13 genes which located within the 7q21.3 locus were detected in HCC, and up-regulated expression of genes was also found in cases of PEG10, SGCE and DYNC1I1. These results suggested that besides PEG10, SGCE and DYNC1I1 may also be probable target genes in the subchromosomal region of 7q21.3. Further studies are needed to explore functional roles of PEG10, SGCE and DYNC1I1 genes might play in the initiation and/or progression of HCC.
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###### Additional file 1

**Subchromosomal regions of amplification and deletion in HCC detected by digital karyotyping**. Digital karyotyping revealed that subchromosomal amplification (fold change ≥3) and deletion (fold change ≤0.1) occurred in multiple chromosomes in HCC.
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###### Additional file 2

**Raw data of real-time quantitative PCR validation for genomic DNA level of SGCE, PEG10, DYNC1I1 and SLC25A13 genes**. Raw data of genomic DNA level of SGCE, PEG10, DYNC1I1 and SLC25A13 genes in 52 normal individuals and 52 HCC samples were presented in this file. Relative genomic DNA level of SGCE, PEG10, DYNC1I1 and SLC25A13 genes were calculated according to the formula 2^Ct(LINE-1)-Ct(target\ gene)^. Student\'s *t*test and Bonferroni correction were applied in the statistical analysis of raw data.
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###### Additional file 3

**Raw data of real-time quantitative RT-PCR detection for SGCE, PEG10 and DYNC1I1 genes**. Raw data of SGCE, PEG10 and DYNC1I1 gene expression level in 32 pairs of HCC and corresponding nontumorous liver tissues determined by real-time quantitative RT-PCR were presented in this file. Relative expression level of DYNC1I1, SGCE and PEG10 genes were calculated according to the formula 2^Ct(GAPDH)-Ct(target\ gene)^. Student\'s *t*test and Bonferroni correction were applied in the statistical analysis of raw data.
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###### Additional file 4

**Data summary of 23 digital karyotyping libraries in public database**. In the 23 digital karyotyping libraries available at <http://cgap.nci.nih.gov/SAGE/DKViewHome>, percentage of tags matched to human genome varied from 48% to 69%, while most of them were between 62% and 69%.
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